サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794503

多系統萎縮症の世界市場

Multiple System Atrophy

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.34円
多系統萎縮症の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

多系統萎縮症の世界市場は2030年までに1億6,350万米ドルに達する見込み

2024年に1億4,520万米ドルと推定される多系統萎縮症の世界市場は、2030年には1億6,350万米ドルに達し、分析期間2024-2030年のCAGRは2.0%で成長すると予測されます。本レポートで分析したセグメントの1つである磁気共鳴画像は、CAGR 2.7%を記録し、分析期間終了時には6,730万米ドルに達すると予測されています。陽電子放射断層撮影（Positron Emission Tomography）セグメントの成長率は、分析期間中CAGR 1.0％と推定されます。

米国市場は3,960万米ドルと推定、中国はCAGR4.1％で成長予測

米国の多系統萎縮症市場は、2024年に3,960万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3,100万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6％と1.5％と予測されています。欧州では、ドイツがCAGR 1.0%で成長すると予測されています。

世界の多系統萎縮症市場- 主要動向と促進要因のまとめ

多系統萎縮症が神経変性疾患調査で注目される理由とは？

多系統萎縮症（MSA）は、中枢神経系の複数の領域を侵し、運動、自律神経、小脳の症状を併発する、まれで進行性の神経変性疾患です。この疾患はパーキンソン病と共通の特徴を有するが、より急速に進行し、ドパミン治療に対する持続的な反応を欠きます。他の運動障害と症状が重複するため、診断は臨床的に困難であり、しばしば介入が遅れます。このような複雑性から、MSAは臨床的にも研究的にも注目されており、特に早期かつ正確な診断がケアプランの立案や臨床試験の登録に重要です。

MSAは2つのサブタイプに分類されます。MSA-P（パーキンソン型）とMSA-C（小脳型）です。どちらの病型もグリア細胞にα-シヌクレインが広範囲に蓄積しており、MSAをパーキンソン病やその他の関連疾患と病理学的に区別しています。治療法は現在のところ対症療法であり、根治的な治療法は存在しないため、薬物療法や支持療法を通じて生活の質を改善することに重点を置いています。このアンメットニーズは、診断、疾患修飾療法、および集学的ケアの枠組みにおける新たなアプローチを推進し続けています。

MSAに対処するために、どのような治療戦略が検討されているのか？

現在の治療戦略は、ドパミン作動性薬剤による運動症状の管理と、血圧、膀胱機能、睡眠障害を安定化させる薬剤による自律神経機能障害への対処を目的とした緩和的なものです。しかし、その効果は限定的で短期間であるため、疾患修飾的な選択肢の緊急の必要性が浮き彫りになっています。現在、いくつかの研究プログラムでは、αシヌクレインの凝集、神経炎症、ミトコンドリア機能障害などを標的としたアプローチが研究されており、これらは疾患進行の根底にあると考えられています。

臨床試験では、神経変性経路に介入する低分子化合物、モノクローナル抗体、遺伝子治療が評価されています。いくつかの治験薬は、グリア細胞の損傷を遅らせたり、脳内の免疫系の活動を調節することを目的としています。幹細胞を用いた治療法などの再生戦略への関心も高まっているが、これらはまだ研究の初期段階にあります。研究が進むにつれて、患者登録、バイオマーカーの同定、画像診断ツールの改良が、研究デザインを洗練させ、より早期の介入を可能にする上で重要な役割を果たしています。

市場力学に影響を与えるヘルスケアシステムと患者ニーズは？

MSAは、その希少性から、運動障害の専門家、自律神経の専門家、リハビリの専門家が連携したケアを提供する専門の神経センターで管理されるのが一般的です。この疾患は、その急速な進行と複数のシステムの関与により、介護者やヘルスケアシステムに大きな負担を強います。患者はしばしば、薬物療法、理学療法、言語療法、支援技術の組み合わせを必要とします。早期に集学的治療と患者教育を受けることで、合併症を遅らせ、日常機能を改善することができます。

世間一般の認知度はまだ低く、診断が不十分で、地域によってケア経路に一貫性がないです。擁護団体は、教育、患者支援、臨床試験参加の拡大に取り組んでいます。診断の不確実性は、的を絞った治療や適切な紹介へのアクセスを妨げ続けています。早期発見を改善し、誤診率を減少させるためには、プライマリケア医や神経内科医の認識を高めることが不可欠であるが、MSAの誤診率は現在も高いままです。

多系統萎縮症市場の成長はいくつかの要因によって牽引...

多系統萎縮症市場の成長は、いくつかの要因によって牽引されています。診断能力と神経画像ツールの向上により、患者の特定とサブタイプ分類が改善されつつあります。希少な神経変性疾患に対する研究投資の増加により、根本的な疾患メカニズムを対象とした臨床試験が増加しています。患者支援ネットワークの拡大は、認知度向上、教育、試験募集を支援しています。バイオマーカー研究と画像診断法の進歩は、早期診断と早期介入を促進します。集学的治療モデルと症状管理戦略への幅広いアクセスは、患者の長期的転帰を改善します。最後に、希少疾病用医薬品の開発支援に対する規制当局の関心は、この困難で十分な治療を受けていない疾患領域における技術革新と投資を加速させる。

セグメント

診断タイプ（磁気共鳴画像、陽電子放射断層撮影、単光子放射コンピュータ断層撮影、傾斜テーブル検査、その他の診断タイプ）、エンドユーザー（病院エンドユーザー、外来手術センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • AC Immune
  • Alterity Therapeutics
  • Asklepios BioPharmaceutical（AskBio）
  • AstraZeneca plc
  • Biohaven Pharmaceuticals
  • Biogen Idec
  • Brain Neurotherapy Bio, Inc.
  • Corestem, Inc.
  • H. Lundbeck A/S
  • Inhibikase Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Modag GmbH
  • Neuramedy
  • ProMIS Neurosciences Inc.
  • Retrotpe
  • Sanofi S.A.
  • Stealth BioTherapeutics Corp.
  • Theravance Biopharma, Inc.
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37463

Global Multiple System Atrophy Market to Reach US$163.5 Million by 2030

The global market for Multiple System Atrophy estimated at US$145.2 Million in the year 2024, is expected to reach US$163.5 Million by 2030, growing at a CAGR of 2.0% over the analysis period 2024-2030. Magnetic Resonance Imaging, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$67.3 Million by the end of the analysis period. Growth in the Positron Emission Tomography segment is estimated at 1.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$39.6 Million While China is Forecast to Grow at 4.1% CAGR

The Multiple System Atrophy market in the U.S. is estimated at US$39.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$31.0 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Multiple System Atrophy Market - Key Trends & Drivers Summarized

Why Is Multiple System Atrophy a Focus Area in Neurodegenerative Disease Research?

Multiple System Atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects multiple regions of the central nervous system, leading to a combination of movement, autonomic, and cerebellar symptoms. The disease shares features with Parkinson’s disease but progresses more rapidly and lacks sustained response to dopaminergic therapy. Diagnosis is clinically challenging due to symptom overlap with other movement disorders, often resulting in delayed intervention. This complexity has placed MSA under increased clinical and research attention, particularly as early and accurate diagnosis is critical for care planning and trial enrollment.

The condition is categorized into two subtypes: MSA-P (parkinsonian) and MSA-C (cerebellar), depending on the predominant symptom profile. Both forms involve widespread alpha-synuclein accumulation in glial cells, distinguishing MSA pathologically from Parkinson’s and other related disorders. Management is currently symptomatic, focusing on improving quality of life through pharmacological and supportive therapies, as no curative treatment exists. This unmet need continues to drive new approaches in diagnostics, disease-modifying therapies, and multidisciplinary care frameworks.

What Therapeutic Strategies Are Being Explored to Address MSA?

Current treatment strategies remain palliative, aimed at managing motor symptoms with dopaminergic agents and addressing autonomic dysfunction with medications that stabilize blood pressure, bladder function, and sleep disturbances. However, limited and short-lived responses highlight the urgent need for disease-modifying options. Several research programs are now investigating approaches that target alpha-synuclein aggregation, neuroinflammation, and mitochondrial dysfunction, which are believed to underlie disease progression.

Clinical trials are evaluating small molecules, monoclonal antibodies, and gene therapies that intervene in neurodegenerative pathways. Some investigational drugs aim to slow glial cell damage or modulate immune system activity within the brain. Interest is also growing in regenerative strategies, including stem cell-based therapies, though these remain at early research stages. As research continues, patient registries, biomarker identification, and improved imaging tools are playing a key role in refining study designs and enabling earlier intervention.

Which Healthcare Systems and Patient Needs Influence Market Dynamics?

Due to its rarity, MSA is typically managed at specialized neurology centers that offer coordinated care from movement disorder specialists, autonomic experts, and rehabilitative professionals. The condition places a high burden on caregivers and healthcare systems due to its rapid progression and multi-system involvement. Patients often require a combination of pharmacological support, physical therapy, speech therapy, and assistive technologies. Early access to multidisciplinary care and patient education can delay complications and improve day-to-day functioning.

Public awareness remains low, leading to underdiagnosis and inconsistent care pathways across different regions. Advocacy organizations are working to expand education, patient support, and clinical trial participation. Diagnostic uncertainty continues to hinder access to targeted treatments and appropriate referrals. Increasing awareness among primary care physicians and neurologists is essential to improve early detection and reduce misdiagnosis rates, which currently remain high for MSA.

Growth in the Multiple System Atrophy Market Is Driven by Several Factors…

Growth in the multiple system atrophy market is driven by several factors. Rising diagnostic capabilities and neuroimaging tools are improving identification and subtyping of patients. Increased research investment in rare neurodegenerative diseases is leading to more clinical trials targeting underlying disease mechanisms. Expansion of patient advocacy networks supports awareness, education, and trial recruitment. Advances in biomarker research and imaging methods facilitate earlier diagnosis and intervention. Broader access to multidisciplinary care models and symptom management strategies improves long-term patient outcomes. Lastly, regulatory interest in supporting orphan drug development accelerates innovation and investment in this challenging and underserved disease area.

SCOPE OF STUDY:

The report analyzes the Multiple System Atrophy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Type (Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test, Other Diagnosis Types); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AC Immune
  • Alterity Therapeutics
  • Asklepios BioPharmaceutical (AskBio)
  • AstraZeneca plc
  • Biohaven Pharmaceuticals
  • Biogen Idec
  • Brain Neurotherapy Bio, Inc.
  • Corestem, Inc.
  • H. Lundbeck A/S
  • Inhibikase Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Modag GmbH
  • Neuramedy
  • ProMIS Neurosciences Inc.
  • Retrotpe
  • Sanofi S.A.
  • Stealth BioTherapeutics Corp.
  • Theravance Biopharma, Inc.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Multiple System Atrophy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Rare Neurodegenerative Disorders Spurs Interest in Multiple System Atrophy (MSA) Therapies
    • Improved Diagnostic Techniques and Clinical Guidelines Enhance Early Detection and Patient Stratification
    • Growing Research Investment in Alpha-Synucleinopathies Drives Drug Development for MSA
    • Increased Focus on Disease-Modifying Therapies Throws Spotlight on Unmet Clinical Needs
    • Collaborative Clinical Trials and Orphan Drug Incentives Accelerate Progress in Experimental Treatments
    • Expansion of Symptomatic Care Options Enhances Market for Neuroprotective and Supportive Drugs
    • Integration of Biomarker Research with Imaging Tools Improves Accuracy in Disease Differentiation
    • Advancements in Gene Therapy and RNA-Based Approaches Create Innovation Pathways for MSA
    • Rising Global Prevalence of Parkinsonism Spectrum Disorders Supports Parallel Market Development
    • Patient Advocacy and Awareness Campaigns Strengthen Funding for Translational MSA Research
    • Healthcare Provider Training Programs Drive Early Diagnosis and Better Clinical Management
    • Improved Access to Multidisciplinary Care Centers Promotes Holistic MSA Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multiple System Atrophy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multiple System Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Multiple System Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Multiple System Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Magnetic Resonance Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Magnetic Resonance Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Magnetic Resonance Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Positron Emission Tomography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Positron Emission Tomography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Positron Emission Tomography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Single Photon Emission Computed Tomography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Single Photon Emission Computed Tomography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tilt Table Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tilt Table Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tilt Table Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Multiple System Atrophy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Multiple System Atrophy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Multiple System Atrophy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Multiple System Atrophy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Multiple System Atrophy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Multiple System Atrophy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Multiple System Atrophy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Multiple System Atrophy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Multiple System Atrophy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Multiple System Atrophy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Multiple System Atrophy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Multiple System Atrophy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Multiple System Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Multiple System Atrophy by Diagnosis Type - Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Multiple System Atrophy by Diagnosis Type - Percentage Breakdown of Value Sales for Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test and Other Diagnosis Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Multiple System Atrophy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Multiple System Atrophy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION